AmpliMed
Tucson
About AmpliMed
AmpliMed Corporation focuses on the development of small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone that has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and benzimidazole Series: benzimidazole analog small molecules that expressed tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $28.4M
- Last round: Series Unknown (Mar 2010)
- Website: amplimed.com
- Phone: 520-529-1000
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/amplimed-3144831 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.